Comparison of hydrofluorosilicic acid and pharmaceutical sodium fluoride as fluoridating agents-A cost-benefit analysis

► Arsenic in current H2O fluoridating agents causes significant cancer treatment costs. ► Arsenic in USP NaF would result in 100-500-fold fewer cancers. ► USP NaF costs about 12 times as much as current fluoridating agents. ► U.S. savings as a society using USP NaF would be $1-5 billion annually. ► Costs and savings are not distributed evenly throughout society.